Skip to content
DataLookout
Menu

NCT03594630

Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer

StatusRecruiting
PhaseEarly Phase 1
Primary completion (estimated)

At risk: Primary completion moved 2 years later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 17 versions: 13 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Oct 31, 2026 to Oct 31, 2028
    • Eligibility criteria expanded, about 18 words
    • Secondary endpoints: details revised at 1 of 7 entries
  2. Study Identification, Study Status, Oversight, Conditionsv14
  3. Study Identification, Study Status, Oversight, Conditionsv13
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 31, 2024 to Mar 13, 2024
    • Site details revised
    v12
  5. Notable Primary and study completion dates: Oct 31, 2024 to Oct 31, 2026
    • Start date: Oct 31, 2023 to Oct 31, 2024
    v11
Show 7 earlier versionsHide 7 earlier versions
  1. Notable Start date: Oct 31, 2022 to Oct 31, 2023v9
  2. Notable Start date: Oct 31, 2020 to Oct 31, 2022v7
  3. Notable Start date: Oct 2019 to Oct 31, 2020
    • Primary completion date: Oct 2024 to Oct 31, 2024
    • Study completion date: Oct 2025 to Oct 31, 2024
    v6
  4. Notable Primary completion date: Jan 2020 to Oct 2024
    • Start date: Jan 18, 2019 to Oct 2019
    • Study completion date: Jan 2020 to Oct 2025
    v5
  5. Notable Primary and study completion dates: Jan 31, 2019 to Jan 2020
    • Start date: Oct 18, 2018 to Jan 18, 2019
    v4
  6. Notable Start date: Aug 18, 2018 to Oct 18, 2018v3
  7. Minor Site contact updatedv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Overall organ preservation rate
Timeframe: At 12 months
Local tumor regrowth rate
Timeframe: At 12 months
Time to surgery or death
Timeframe: Up to 12 months

Secondary (7)

Decision quality assessment determined by European Organization for Treatment and Research of Cancer Quality of Life Questionnaire (EORTC-QLQ30+CR29)
Overall survival (OS)
Regression-free survival (RFS)
Incidence of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
Surgical success rates
Show 2 moreShow less
Radiographic Findings
Pathologic Findings

Arms and interventions

Group I (surgical resection)Active comparator

Participants who have achieved clinical complete response undergo standard surgical resection.

Group II (active surveillance)Experimental

Participants who have achieved clinical complete response receive active surveillance and consolidated chemotherapy for up to 4 months in the absence of disease progression or unacceptable toxicity. Participants with incomplete response or regrowth of tumor, undergo surgical resection as in Group I.

Drugs: Chemotherapy

Other: Patient Observation, Questionnaire Administration

Procedures: Resection of Rectum

Sites

1 site in 1 country

  • M D Anderson Cancer CenterHouston, Texas, United States